Quantcast
Last updated on April 18, 2014 at 17:24 EDT

Latest Hydrocodone Stories

2013-09-03 23:22:57

In Ohio, prescription drug abuse is rising at a very high rate and is a leading cause of death in the state. Illustrating the importance of early detection of drug abuse, those with substance abuse issues should contact a detox center like Harbor Village. (PRWEB) September 03, 2013 According to The Intelligencer / Wheeling News-Register article on 8/28, Curbing Abuse of Painkillers, that in Ohio, prescription drug abuse is rising at a very high rate and is a leading cause of death in the...

2013-08-26 08:28:20

Clinical Study Also Indicates No Systemic Prodrug Exposure Over Multiple-Day Dosing at Maximum Daily Dose NORTH LIBERTY, Iowa, Aug. 26, 2013 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, today announced positive results from one of several clinical and non-clinical studies that the company is performing in preparation for its New Drug Application (NDA) for KP201...

2013-08-13 08:30:33

ATLP-03 uses SMART/Script(TM) drug delivery technology to deter prescription drug abuse ATLANTA, Aug. 13, 2013 /PRNewswire/ -- Atlantic Pharmaceuticals, Inc., a specialty pharmaceutical company that has developed and is commercializing a unique technology to deter prescription drug abuse today announced that it has completed a successful Pre-Investigational New Drug Meeting with the Food and Drug Administration on a single component, immediate release, abuse-deterrent hydrocodone...

2013-08-07 08:29:35

NORTH LIBERTY, Iowa, Aug. 7, 2013 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application titled, "Phenylethanoic Acid, Phenylpropanoic Acid and Phenylpropenoic Acid Conjugates and Prodrugs of Hydrocodone, Method of Making and Use Thereof."...

2013-06-26 20:39:32

Patients in moderate to severe pain in emergency rooms across the U.S. are less likely to receive opioid pain medications if they are black, Hispanic, poor, or have less education, compared to more affluent patients, according to a University of Rochester Medical Center study reported in the Journal of General Internal Medicine. The study took place against the backdrop of a national epidemic of narcotics abuse, combined with a need to satisfy patients’ legitimate complaints of pain....

2013-06-12 08:29:12

PISGAH FOREST, N.C., June 12, 2013 /PRNewswire/ -- As controversy surrounds the recent FDA decisions concerning abuse deterrent forms of oxycodone drug products, Pisgah Laboratories, Inc. (www.pisgahlabs.com) achieves another technical milestone which may radically alter the landscape for pain medication regulations. Recently, the FDA ruled that the Abbreviated New Drug Applications (ANDAs) -- competitive to Purdue Pharma's branded Oxycodone® -- would no longer be considered if they did...

2013-06-11 12:28:37

WASHINGTON, June 11, 2013 /PRNewswire-USNewswire/ -- The Center for Lawful Access and Abuse Deterrence (CLAAD) joined in signing a Citizen Petition filed today urging the Food and Drug Administration (FDA) to fully implement the Obama administration's policy supporting a market transition to safer opioid medications. The petition asks that the FDA reject applications for new opioid medications without added safety features. Opioids are a class of synthetically derived chemicals often used to...

2013-06-11 11:16:32

New findings provide vital step towards exploring pain medications that may lower risks of prescription drug abuse and side effects of painkillers For patients managing cancer and other chronic health issues, painkillers such as morphine and Vicodin are often essential for pain relief. The body's natural tendency to develop tolerance to these medications, however, often requires patients to take higher doses — increasing risks of harmful side effects and dependency. Now, new...

2013-06-11 08:32:29

NORTH LIBERTY, Iowa, June 11, 2013 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 8,461,137 to KemPharm for its patent application entitled, "Benzoic Acid, Benzoic Acid Derivatives and Heteroaryl Carboxylic Acid Conjugates of Hydrocodone, Prodrugs, Methods of Making and Use Thereof." The...

2013-06-04 08:30:17

Poster Presentation to Highlight KP201's Unique Abuse-Deterrent Properties and Its Potential to Prevent or Reduce Opioid-Induced Constipation NORTH LIBERTY, Iowa, June 4, 2013 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that that its Vice President of Research, Sven Guenther, Ph.D., will present a poster on the Company's novel pain drug candidate, KP201, at...